PMS2 and colorectal carcinoma: In the univariable logistic regression, men had 62% higher odds of developing CRC than women, and patients with a PMS2 gene mutation had lower odds of developing CRC than MLH1 gene carriers (OR=0.37, 95% CI: 0.15–0.94).